Trademark: NEPOR 1697679
Word
NEPOR
ID
1697679
Trademark Type
Word
Status
Registered: Registered/protected
Application Date
04 June 2015
Registration Date
04 June 2015
Renewal Date
04 June 2025
Owner(s)
Service
Spruson & Ferguson
Goods and Services:
Class 5:
Diagnostic kits comprised of medical diagnostic reagents, including reagents for testing, determining and/or analyzing the level of protein and/or RNA expression in a biological sample derived from an individual, in particular the level of EPH-B4 and/or Ephrin A1 receptor expression in a sample derived from tumor tissue or bodily fluids; diagnostic assays for testing of cells, tissue or bodily fluids for use in patient stratification and disease detection, including cancer; biological and medical preparations and articles, including reagents for use in diagnostic and clinical tests, diagnostic biomarker reagents for medical purposes, including for enabling treatment decisions in connection with cancer patients, in particular with the administration of erythropoietin; pharmaceuticals and therapeutics, including for use in precision medicine; none of the aforesaid being in relation to wound care
Diagnostic kits comprised of medical diagnostic reagents, including reagents for testing, determining and/or analyzing the level of protein and/or RNA expression in a biological sample derived from an individual, in particular the level of EPH-B4 and/or Ephrin A1 receptor expression in a sample derived from tumor tissue or bodily fluids; diagnostic assays for testing of cells, tissue or bodily fluids for use in patient stratification and disease detection, including cancer; biological and medical preparations and articles, including reagents for use in diagnostic and clinical tests, diagnostic biomarker reagents for medical purposes, including for enabling treatment decisions in connection with cancer patients, in particular with the administration of erythropoietin; pharmaceuticals and therapeutics, including for use in precision medicine; none of the aforesaid being in relation to wound care
Class 44:
Medical testing for diagnostic or treatment purposes; molecular testing for medical purposes; consulting services in the field of diagnostic medical testing and precision medicine, including those services relating to treatment decisions and the administration of cancer drugs; health care consulting in the field of cancer treatment; providing online information, via the Internet and mobile applications, in the fields of genetic and molecular testing and cancer diagnosis and treatment; medical and pharmaceutical consulting services relating to patient specific medical treatment options, including cancer treatment options; medical consulting services relating to the treatment and diagnosis of individuals; providing pharmaceutical and medical information, including information about drug safety and drug compatibility in relation to cancer therapy and the treatment of individuals, in particular in connection with the administration of erythropoietin; medical consulting services in the fields of patient treatment and treatment protocols, diagnostic molecular testing, drug safety, dosage assessment, including in the field of cancer treatment therapy for others; none of the aforesaid being in relation to wound care
Medical testing for diagnostic or treatment purposes; molecular testing for medical purposes; consulting services in the field of diagnostic medical testing and precision medicine, including those services relating to treatment decisions and the administration of cancer drugs; health care consulting in the field of cancer treatment; providing online information, via the Internet and mobile applications, in the fields of genetic and molecular testing and cancer diagnosis and treatment; medical and pharmaceutical consulting services relating to patient specific medical treatment options, including cancer treatment options; medical consulting services relating to the treatment and diagnosis of individuals; providing pharmaceutical and medical information, including information about drug safety and drug compatibility in relation to cancer therapy and the treatment of individuals, in particular in connection with the administration of erythropoietin; medical consulting services in the fields of patient treatment and treatment protocols, diagnostic molecular testing, drug safety, dosage assessment, including in the field of cancer treatment therapy for others; none of the aforesaid being in relation to wound care